Inactive Instrument

Analyst Reco. Cytokinetics, Inc. Nasdaq

Equities

US23282W1009

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 26	Cytokinetics Appoints Sung Lee as CFO	MT
Apr. 26	Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	Apr. 09	MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating	Mar. 06	MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61	Jan. 24	MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating	Jan. 19	MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market	Jan. 08	MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept	Dec. 27	MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating	Dec. 27	MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating	Dec. 27	MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating	Dec. 27	MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target	Nov. 09	MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated	Nov. 07	MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating	Nov. 03	MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating	23-10-20	MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating	23-10-09	MT
SVB Initiates Cytokinetics at Outperform	23-08-15	MT
JPMorgan Raises Cytokinetics' Price Target to $54 From $52, Maintains Overweight Rating	23-06-22	MT
UBS Adjusts Cytokinetics Price Target to $62 From $61, Maintains Buy Rating	23-05-05	MT
UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating	23-04-03	MT
Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating	23-04-03	MT
JPMorgan Chase Adjusts Price Target on Cytokinetics to $52 From $55, Maintains Overweight Rating	23-03-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cytokinetics, Inc. Nasdaq

Equities

US23282W1009

Analyst Reco.

Filters